LENSAR Inc (NAS:LNSR)
$ 8.68 +0.28 (+3.33%) Market Cap: 106.64 Mil Enterprise Value: 95.46 Mil PE Ratio: 0 PB Ratio: 7.15 GF Score: 61/100

Q2 2026 LENSAR Inc Earnings Call Transcript

Aug 13, 2026 / 12:30 PM GMT
Release Date Price: $8.27 (+31.48%)

Key Points

Positve
  • LENSAR Inc (LNSR) delivered 18% total revenue growth in Q2 2026, reaching $16.5 million, with recurring revenue up 20% to $13.7 million, representing 83% of total revenue.
  • Procedure revenue grew 23% year-over-year to $10.2 million, with procedure volume up 13% to 58,682 procedures, and the company's systems performed 31% more procedures than the national average.
  • The company achieved its strongest adjusted EBITDA performance to date at $3.6 million, and reported GAAP net income of $3.5 million, a significant improvement from a net loss of $1.8 million in the prior year period.
  • US procedure market share expanded to 24.1% in Q2 2026, up from 23.4% in Q1 2026 and 21.4% in Q2 2025, reflecting continued competitive gains.
  • The installed base of Ally systems grew 30% year-over-year to approximately 215 systems, with 10 placements in the quarter and a backlog of 13 systems, providing visibility into future growth.
  • Gross margin remained stable at approximately 50%, supported by a $1.1 million tariff refund and a higher contribution from the growing recurring revenue stream.
Negative
  • Cash and cash equivalents decreased to $13.6 million at the end of Q2 2026, down from $18 million at the end of 2025, reflecting investments in inventory and working capital.
  • The company expects operating expenses to trend modestly higher in the coming quarters as it increases investment in commercial efforts, which could pressure near-term profitability.
  • Management noted that Q3 is historically the lowest quarter for cataract surgery procedures due to summer vacations and holidays, which could impact revenue growth in the near term.
  • The company is still in the early stages of rebuilding its distributor relationships in international markets, particularly in Europe, following the terminated merger with Alcon, which may take several quarters to fully recover.
  • There is expected variability in ASPs and revenue due to a mix of US and international system sales, with international distributor sales typically generating lower procedure ASPs.
  • The company faces potential pricing pressure from highly leveraged private equity groups that own practices, which could lead to fluctuations in system pricing and procedure revenue.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

LNSR.OQ - LENSAR Inc
Q2 2026 LENSAR Inc Earnings Call
Aug 13, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to Lensar Inc.

Second quarter 2026 results conference call.

At this time, all participants are in a listen-only mode.

After the speaker's presentation, there will be a question-and-answer session.

To ask the question during the session, you will need to press 11 on your telephone.

You would then hear an automated message advising your hand is raised.

To with all your question, please press 11 again.

I would now like to turn the call over to Lee Roth, President of Burns McClellan, investor relations advisor to Linsar.

Mr.

Roth, please go ahead.

Thanks, Tawanda.

Good morning everyone, and once again welcome to the Lenzar second
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot